Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-7 of 7 (Search time: 0.002 seconds).
previous
1
next
Item hits:
Preview
Issue Date
Title
Author(s)
2014
Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint
Branford, S.
;
Ross, D.
;
Yeung, D.
;
Braley, J.
;
Hughes, T.
;
56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2014
The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Parker, W.
;
Braley, J.
;
Seymour, J.
;
Hughes, T.
;
56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Branford, S.
;
Yeung, D.
;
Parker, W.
;
Roberts, N.
;
Purins, L.
;
Braley, J.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Donaldson, Z.
;
Leong, M.
;
Fletcher, L.
;
Seymour, J.
;
Grigg, A.
;
Ross, D.
;
Hughes, T.
2014
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination
Parker, W.
;
Phillis, S.
;
Yeung, D.
;
Hughes, T.
;
Scott, H.
;
Branford, S.
2014
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
Hughes, T.
;
Lipton, J.
;
Spector, N.
;
Cervantes, F.
;
Pasquini, R.
;
Clementino, N.
;
Dorlhiac Llacer, P.
;
Schwarer, A.
;
Mahon, F.
;
Rea, D.
;
Branford, S.
;
Purkayastha, D.
;
Collins, L.
;
Szczudlo, T.
;
Leber, B.
2014
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Olshen, A.
;
Tang, M.
;
Cortes, J.
;
Gonen, M.
;
Hughes, T.
;
Branford, S.
;
Quintás-Cardama, A.
;
Michor, F.
2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
Baccarani, M.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Mongay, L.
;
Mone, M.
;
Ortmann, C.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
;
Cortes, J.
;
Guilhot, F.
Discover
Author
4
Yeung, D.
3
Braley, J.
3
Parker, W.
3
Ross, D.
2
56th ASH Annual Meeting (6 Dec 20...
2
Cortes, J.
2
Phillis, S.
2
Seymour, J.
1
Altamura, H.
1
Baccarani, M.
.
next >
Subject
3
Benzamides
3
Fusion Proteins, bcr-abl
3
Piperazines
3
Pyrimidines
2
Antineoplastic Agents
2
Leukemia, Myelogenous, Chronic, B...
1
Artifacts
1
Gene Expression
1
Imatinib; Chronic myeloid leuke...
1
Mutation
.
next >